Overview

A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia

Status:
Terminated

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the efficacy of satavaptan versus placebo in participants with dilutional hyponatremia due to SIADH. Secondary objectives are to assess the safety of satavaptan, the maintenance of effect, and the clinical benefit in these participants.

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

Satavaptan